ADC Therapeutics S.A.
ADCT News Today: Stay Updated with the Latest ADC Therapeutics S.A. News in Real Time
Find ADCT news now at Meyka AI. Stay informed with the latest ADC Therapeutics S.A. stocks updates, including price news, market analysis, and expert insights.
MNKD Stock Surges 24% on United Therapeutics Ralinepag Deal Expansion
MNKD stock jumps 24.5% after MannKind expands collaboration with United Therapeutics on ralinepag DPI program for pulmonary hypertension.
MBCI Stock Plummets 99.75% on Pink Sheets Exchange Today
MBCI stock crashes 99.75% to $0.000001 on PNK exchange. MabCure Inc. faces severe liquidity crisis with $7,322 market cap and negative fundamentals.
GMAB Earnings Preview: Genmab Q1 2026 on May 7
Genmab (GMAB) reports Q1 2026 earnings May 7. Analysts expect $0.15 EPS, $905.77M revenue. Stock at $27.52.
Bayer to acquire Perfuse Therapeutics in deal worth up to $2.45 billion
Bayer announced on May 6, 2026, that it will acquire Perfuse Therapeutics in a deal worth up to $2.45 billion. The move strengthens Bayer’s focus on eye care and new treatments for vision loss. Perfuse is known for its experimental drug PER-001, aimed at serious eye diseases. The deal shows how big pharma companies are…
UTHR Insider Selling: CFO and CEO Dispose Stock Options May 2026
United Therapeutics insiders sell $2.7M in stock options. CFO Edgemond and CEO Rothblatt dispose shares on May 4, 2026.
ALDEI.PA Stock Surges 13% in Pre-Market Trading on May 6
ALDEI.PA: Deinove SA biotech stock trading €0.0265 on EURONEXT. Developing antibiotic DNV3837 for C. difficile infections with 13M share volume.
SGMO Stock Surges 31.5% as Sangamo Therapeutics Nears May 11 Earnings
SGMO stock jumped 31.5% to $0.1776 on May 5, 2026. Sangamo Therapeutics reports Q1 earnings Monday with analyst expectations of $0.0050 EPS.
TVTX Earnings Miss: Travere Therapeutics Q1 2026 Results
Travere Therapeutics missed Q1 2026 earnings estimates with EPS of -$0.39 vs -$0.24 expected and revenue of $127.2M vs $136.2M forecast.
VRTX Vertex Pharmaceuticals Q1 2026 Earnings Beat EPS
Vertex Pharmaceuticals beat EPS estimates with $4.47 vs $4.24 expected, but revenue missed slightly at $2.99B on May 4, 2026.